Safe Use of Memantine in a Pediatric Patient With Catatonia

J Am Acad Child Adolesc Psychiatry. 2022 Dec;61(12):1401-1403. doi: 10.1016/j.jaac.2022.05.007. Epub 2022 Jun 8.

Abstract

Pediatric catatonia is a complex neuropsychiatric syndrome. Benzodiazepines are standard first-line pharmacotherapy. When benzodiazepines do not provide relief of symptoms, electroconvulsive therapy (ECT) is the most proven effective therapy. However, the use of NMDA antagonists (amantadine and memantine) has been reported effective in adult patients as adjuncts and may provide an alternative treatment modality when ECT is not readily accessible. To the author's knowledge there are no prior case reports of memantine used in pediatric catatonia. This case demonstrates the safe use of memantine as an adjunctive agent in an adolescent with catatonia.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Amantadine / adverse effects
  • Benzodiazepines / adverse effects
  • Catatonia* / diagnosis
  • Catatonia* / drug therapy
  • Electroconvulsive Therapy* / adverse effects
  • Humans
  • Memantine / adverse effects

Substances

  • Amantadine
  • Benzodiazepines
  • Memantine